GlassScriptPhysician profile
Mark Kontos
NPI 1114938990
$175,341.89
in general payments reported to CMS, 2019-2025
33 companies · $27K in 2025
The $27K reported for 2025 was more than what 97% of Ophthalmology providers received nationally (typical 2025 total: $384).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $36K · 2020: $13K · 2021: $28K · 2022: $12K · 2023: $30K · 2024: $29K · 2025: $27K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $69K · Food and Beverage: $11K · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $3,663 · Honoraria: $1,826 · Travel and Lodging: $636.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $68,963.00 |
| Food and Beverage | $10,904.00 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $3,662.50 |
| Honoraria | $1,825.59 |
| Travel and Lodging | $635.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Johnson & Johnson Surgical Vision, INC. | $76,627.61 | 2019-2025 | Tecnis Simplicity, Compact Intuitiv, Ifs Advanced Femtosec Laser |
| Carl Zeiss Meditec, INC. | $27,870.43 | 2019-2025 | Iolmaster 700, Forum Glaucoma Workplace, Humphrey Hfa |
| Rxsight INC | $16,290.84 | 2021-2025 | Rxsight Contact Lens, Rxsight Injector Cartridge, Rxsight Light Delivery Device (Ldd) |
| Alcon Vision LLC | $10,946.14 | 2019-2025 | Acrysof Iq Vivity, Acrysof Iq Panoptix Uv Iol, Clareon |
| Allergan, INC. | $7,689.21 | 2019-2022 | |
| Avedro INC. | $6,376.30 | 2019 | |
| Novartis Pharmaceuticals Corporation | $5,063.20 | 2019-2022 | |
| Shire North American Group INC | $4,244.99 | 2019 | |
| Abbvie INC. | $3,546.03 | 2023-2025 | |
| Glaukos Corporation | $2,784.52 | 2019-2025 | Kxl System (Not Refurbished), Kxl System, Istent Trabecular Micro-Bypass System Model Is3 |
| Eyepoint US, INC. | $2,491.11 | 2019 | |
| Bausch & Lomb Americas INC. | $2,045.81 | 2022-2025 | Miebo, Xiidra, Vyzulta |
| Horizon Therapeutics Plc | $1,875.49 | 2023 | Tepezza |
| Lensar, INC. | $1,522.71 | 2019-2023 | Lensar Laser System |
| Sun Pharmaceutical Industries INC. | $1,484.24 | 2019-2025 | Cequa, Bromsite, Xelpros |
Show all 33 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Carl Zeiss Meditec USA, INC. | $1,317.66 | 2021-2022 | |
| Kala Pharmaceuticals, INC. | $1,300.00 | 2021 | |
| Tarsus Pharmaceuticals, INC. | $530.80 | 2024-2025 | Xdemvy |
| Johnson & Johnson Vision Care, INC. | $301.51 | 2022-2024 | Tecnis Simplicity |
| Biotissue Holdings INC. | $235.03 | 2022-2023 | |
| Harrow Eye, LLC | $157.74 | 2023-2025 | Natacyn, Tobradex St, Iheezo |
| Omeros Corporation | $137.65 | 2019 | |
| Oyster Point Pharma, INC. | $122.35 | 2022-2024 | Tyrvaya, Ryzumvi |
| Mallinckrodt Hospital Products INC. | $114.68 | 2023-2024 | Acthar |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $45.87 | 2019-2021 | |
| Lumibird Medical INC. | $40.10 | 2025 | |
| Astellas Pharma US INC | $34.45 | 2024 | Izervay |
| Rayner Intraocular Lenses Limited | $33.35 | 2023 | Rayone Aspheric, Omidria, Rayone Emv |
| Genentech USA, INC. | $30.57 | 2024 | Vabysmo |
| Dompe US, INC. | $23.66 | 2025 | Oxervate |
| Thea Pharma INC. | $23.07 | 2023 | Iyuzeh |
| Carl Zeiss Meditec Ag | $19.40 | 2020 | |
| Ivantis, INC | $15.37 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mark Kontos listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.